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Abstract
Background: PRRS is a viral disease of pigs and sows that is one of the most costly to the pig industry worldwide.
The disease can be controlled by focusing on different aspects. One of them is the vaccination of piglets, which is
more controversial and difficult to manage than the vaccination of sows. However, pig producers could consider a
piglet vaccination strategy if it reduces the negative clinical disease and improves zootechnical performance,
decreases the probability to be infected and/or reduces the spread of the virus once the vaccinated piglet is
infected. The efficacy of a novel PRRS modified live vaccine (Ingelvac PRRSFLEX® EU) was studied in a blinded, side-
by-side placebo controlled field study of piglet vaccination including piglets weaned for three consecutive weeks
(week groups 1, 2 and 3).
Results: This study established that PRRS piglet vaccination resulted in significantly better weight gain, seen as
early as 4 weeks after vaccination, in naturally challenged pigs. Vaccine efficacy was supported by statistically
significant increases in Average Daily Weight Gain (ADWG) among week group 3 vaccinated pigs from vaccination
to the end of the study and statistically significant increases in bodyweight and ADWG from inclusion to 10 weeks
of age in week group 2 vaccinated piglets. However, no differences were noted in week group 1 presumably
because more than 30 % of the vaccinated pigs were viremic at the time of vaccination. Furthermore, the
proportion of pigs showing any abnormal clinical sign at least once at any of the examination time points was
lower in vaccinated pigs than in control pigs. Based on the viremia results (qPCR), early onset of PRRS was detected
in this herd. Viremia occurred at the time of vaccination in week group 1 and shortly after vaccination in week
groups 2 and 3. Peak wild type PRRSV infection was assumed at 4 weeks post vaccination in all groups based on
the number of PRRS positive pigs in the control groups.
Conclusion: This study establishes that vaccination of piglets with Ingelvac PRRSFLEX® EU at 4 weeks of age
improves weight gain and reduces the appearance of clinical sings during the growing period, even when the
piglets are infected shortly after vaccination.
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Background
Porcine Reproductive and Respiratory Syndrome (PRRS) is
a viral disease of pigs and sows that is one of the most
costly to the pig industry worldwide. Nieuwenhuis et al. [1]
have calculated a decrease of 1.7 pigs sold per sow during
the outbreak period in The Netherlands while in North
America 1.44 weaned pigs per sow/year were lost to PRRS
[2]. Increasing costs of PRRS between 2005 and 2010 were
estimated between 3 and 109 € per sow in Europe [1] and
at 2.36$ per pig weaned in US [2].
The disease can be controlled by focusing on different
management aspects. Different strategies must be taken
into account by veterinarians once a herd has become in-
fected and often include: the fast and reliable diagnosis of
an outbreak, internal and external biosecurity measures,
control of secondary infections and immunization.
Nowadays, live attenuated and inactivated vaccines are
available globally. Also strategies of injections with
serum containing live PRRS virus (PRRSV), so called
Live Virus Inoculation (LVI) have been used to consist-
ently expose the sow herd [3] but neither of them, vac-
cines or LVI inoculation are considered to have a high
efficacy specially when applied to piglets [4, 5]. Due to
the high genetic variability of the virus [6, 7] almost all
the infections in the field can be considered as heterol-
ogous to existing vaccines [8].
The vaccination of piglets is more controversial among
European Veterinarians and difficult to manage (timing
and compliance) than the vaccination of sows due to the
fact that i) if naïve piglets are infected with genotype 1
PRRSV, the clinical signs of the respiratory disease are
not always evident [9], ii) because there is frequent inter-
action with other pathogens which affects the clinical
expression of the symptoms [10] and iii) if the propor-
tion of viremic piglets after weaning is high, the time
needed to generate an effective immunity is probably
longer than the infection time [11].
Piglet vaccination strategies could be taken into ac-
count by the producers if i) the vaccination of piglets de-
creases the probability to be infected and/or ii) if the
vaccination of piglets reduces the spread of the virus
once the vaccinated piglet is infected.
Average daily gain and mortality are the performance
variables most affected by PRRSV status of piglets [2].
Neither feed conversion rate nor the percentage of pigs
sold to the primary market are commonly affected by
the PRRSV status of piglets in outbreaks with type 1
virus [2] even though in some cases differences in feed
conversion rate has been found [12].
The present study was designed to investigate the effi-
cacy of Ingelvac PRRSFLEX® EU vaccine in 4 week old
piglets under field conditions to prevent the productive
and clinical effects caused by PRRSV. Primary parame-
ters of vaccine efficacy were the productive performance
based on the Bodyweight (BW) and the Average Daily
Weight Gain (ADWG). Secondary parameters investi-
gated were viremia, serological response, mortality, clin-
ical signs and concomitant treatments.
Methods
Animals and experimental design
The study was performed under normal husbandry field
conditions according to Good Clinical Practice (GCP VICH
GL9) in two treatment groups. The trial was designed as a
randomized, blinded and included an unvaccinated negative
control group of piglets. The treatment group received a
single intramuscular administration of Ingelvac PRRSFLEX®
EU vaccine (PRRS 94881 Modified Live Virus (MLV; vacci-
nated group) at the minimum titer level indicated for use,
while the other group received 1 mL of Phosphate Buffered
Saline (PBS) intramuscularly as a negative control group
(unvaccinated group). The primary efficacy parameter was
weight gain and was compared between vaccinated and un-
vaccinated pigs. Secondary parameters of the study were
mortality, viremia, serology and clinical signs.
A total of 1364 commercial crossbreed pigs (healthy
by clinical observation) were included in the study at
4 weeks of age and were distributed to two treatment
groups: 690 pigs were administered Ingelvac PRRSFLEX®
EU (vaccinated pigs) and 674 pigs a PBS solution (un-
vaccinated pigs). Three replicates of vaccinated and
unvaccinated pigs were included in the study in con-
secutive weeks: 224, 230 and 236 vaccinated pigs were
included in the first Week Group (WG 1), the second
Week Group (WG 2) and the third Week Group (WG
3), respectively, and 214, 226 and 234 unvaccinated pigs
in WG 1, WG 2 and WG 3, respectively. Study pigs were
weaned at 3 weeks of age from the same sow farm.
Treatment groups were balanced by sex and initial body-
weight within each replication group. The animal phase
finished at the end of the fattening period that was con-
sidered when the first pig from each replicate group was
ready to go to slaughter.
The selected farm had a previous history of PRRS in-
fection with clinical signs in grower-finisher pigs and
was confirmed in a herd pre-screening with PRRSV ser-
ology and quantitative Polymerase Chain Reaction
(qPCR). Positive qPCR samples were sequenced (Open
Reading Frame (ORF) 5) to ensure a heterologous field
challenge. In addition, animals were tested for Actinoba-
cillus pleuropneumoniae (APP), Swine Influenza Virus
(SIV) and Porcines Circovirus Type 2 (PCV2). Sows
from the breeding herd were vaccinated with a commer-
cial live attenuated PRRSV vaccine; therefore, seroposi-
tive pigs born from vaccinated sows were included in
the study. Pigs were fed a commercial ration appropriate
for their age and weight. Feed and water were available
ad libitum.
Cano et al. Porcine Health Management  (2016) 2:22 Page 2 of 8
All study pigs were housed in barns appropriate for
their breed and age, and were kept under similar condi-
tions of climate, air quality, ventilation, temperature, air
humidity and light. In the post-weaning facilities, pigs
from the week groups were distributed in different
rooms. WG 1 in rooms 1, 2, 7 and 8; WG 2 in rooms 3,
4, 5 and 6 and WG 3 in rooms 1, 2, 9 and 10 (see Fig. 1).
Piglets of different WG in the same room were kept in
separate pens. Vaccinated pigs were housed separately
from the unvaccinated pigs until entry into fattening.
Due to the different sizes of rooms, the randomization
of the rooms to the treatment groups was done consid-
ering the room effect. Cross-contamination was pre-
vented by strict biosecurity rules implemented on the
farm for the duration of the study. In the fattening facil-
ities, vaccinated and unvaccinated pigs were commingled
and distributed in three buildings.
Pigs were individually weighed at four time points: at vac-
cination prior to administration of Ingelvac PRRSFLEX® EU
or PBS, at 4 weeks post-vaccination, at the beginning of fat-
tening (10 weeks post-vaccination) and at the end of the
study. For WG1 and WG2, the end of the study was at
17 weeks post-vaccination and for WG 3 at 16 weeks post-
vaccination. ADWG for the intervals between weighing at
vaccination and weighing at 4, 10 and 16–17 weeks post-
vaccination were calculated for each pig individually.
Homogeneity of the BW at the end of the study was calcu-
lated from Coefficient of Variation (1-CV) for every group
and within week group.
Mortality was recorded throughout the study for cal-
culation of the mortality rate. Furthermore, study pigs
were clinically examined at weeks 4, 10, 14 and 16 or 17
post-vaccination. Special attention was given to the re-
spiratory signs (dyspnea, cough) and apathy, but skin al-
terations (petechiae, crust, anemia or icterus), joint
disorders and diarrhea were also recorded. Collective
and individual treatments were also recorded throughout
the study.
Collection and processing of samples
Blood samples were collected from 73 vaccinated (24, 23
and 26 in WG 1, WG 2 and WG 3, respectively) pigs
and 69 unvaccinated pigs (22, 24 and 23 in WG 1, WG
2 and WG 3, respectively). In each pen, at least one pig
of middle weight was chosen to be bled at vaccination
time. Blood samples were drawn prior to administration
of Ingelvac PRRSFLEX® EU or PBS. Additional blood
samples were collected from the same pigs at 4, 10, 14
and 16 or 17 weeks after vaccination. Blood samples
were collected by jugular venipuncture using 4 mL dry
vacuum tubes and were processed within 24 h after col-
lection in order to obtain serum by centrifugation at
3000 rpm during 10 min. Serum samples were stored
frozen at −80 °C until the end of the study. Then, the
serum samples were sent to Boehringer Ingelheim Veter-
inary Research Center GmbH & Co. KG to be tested for
PRRS antibodies by ELISA (HerdChek PRRS X3 Anti-
body Test Kit,IDEXX Laboratories, Inc.), and detection
of PRRSV-EU specific RNA via real-time reverse tran-
scription PCR. Proportions of positive animals were cal-
culated per time point of examination.
Vaccine and placebo product description
Piglets were vaccinated intramuscularly in the neck with
one dose (1 ml) of Ingelvac PRRSFLEX® EU vaccine with
a minimum titer as indicated on the vaccine label in-
structions at 4-weeks of age. Control animals were ad-
ministered one dose of vaccine corresponding solvent
(PBS) without vaccine content. No other vaccinations or
treatments were administered to the animals on at least
3 days before and after the PRRS vaccine treatment.
Data analysis
Statistical analysis was performed with R software [13].
All tests were designed as two-sided tests and differences
were considered as statistically significant if p ≤ 0.05 For
BW and ADWG, differences between treatment groups
were tested using analysis of variance and subsequent t-
tests. Treatment group (PRRS 94881 MLV or PBS), week
group (WG 1, WG 2 or WG 3), their interaction
(Group*WG) and sex (male or female) were included as
factors in the statistical model. The initial weight (BW at
vaccination time) was used as covariate for all post-
treatment time points and for all periods. Least squares
means of the groups and differences between least
squares means with 95 % Confidence Intervals (95 % CI)
were calculated from the analysis of variance. Homogen-
eity at final BW was tested comparing variances of BW
at the end of the study using a Fisher’s test. Differences
in proportions (qPCR positive, ELISA positive, mortality
rate, clinical observations and concomitant treatments)
between the treatment groups were tested by Fisher’s
Fig. 1 Layout of the pigs at weaning
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exact test. Wilson’s confidence interval for a single pro-
portion was also calculated for every proportion.
Results
The farm showed a high degree of PRRSV positive animals
in a pre-screening before the study started. Positive qPCR
samples were sequenced (ORF 5, see Additional file 1)
and results showed identities of 88.94, 88.45 and 92.74 %
to Lelystad virus (GenBank Accession Number: M96262),
Porcilis® PRRS (the PRRSV isolate of the commercial live
attenuated PRRS virus vaccine used in sows; GenBank
Accession Number: KJ127878) and Ingelvac PRRSFLEX®
EU (GenBank Accession Number: KT988004), respect-
ively. Moreover, the pre-screening revealed pigs were posi-
tive for APP, SIV and PCV2 antibodies.
BW and ADWG from vaccinated and unvaccinated
pigs are shown in Table 1. Vaccinated pigs showed better
growth parameters than unvaccinated pigs at 10 weeks
after vaccination. Nevertheless, looking at the 3 week
groups separately, there were differences (p < 0.05) be-
tween vaccinated and unvaccinated pigs in WG 2 and
WG 3 but not in WG 1 (Table 1).
The BW of vaccinated pigs fromWG 2 at 4 and 10 weeks
after vaccination was higher (p < 0.05) than unvaccinated
pigs within the same WG. ADGW increased from vaccin-
ation to 4 and 10 weeks after vaccination (p < 0.05;
Table 1).
The BW in WG 3 of vaccinated pigs was higher (p <
0.05) at week 16 after vaccination and ADWG increased
from vaccination to 16 weeks after vaccination (p < 0.05;
Table 1).
The BW uniformity at the end of fattening was better
in vaccinated pigs than in unvaccinated (p < 0.05;
Table 1). Taking into account week groups separately,
the BW uniformity of vaccinated pigs improved only in
WG 3 (p < 0.05; Table 1) and there were not differences
between groups (p > 0.05) in WG 1 and WG 2.
Percentage of PRRSV RNA positive pigs by qPCR
throughout the study is shown in Figs. 2 and 3 for vacci-
nated and unvaccinated pigs. Peak of viremia with 80 %
(68–88; 95 % CI) of vaccinated pigs and 83 % (72–91 %;
95 % CI) of unvaccinated pigs tested positive was at
4 weeks after vaccination. For all the time points, no dif-
ferences were observed in the prevalence of viremic ani-
mals between vaccinated and unvaccinated pigs. For pigs
in WG1, the PRRSV field infection was on-going at vac-
cination time with 38 % (19–59 %; 95 % CI) of vacci-
nated pigs and 27 % (11–50 %; 95 % CI) of unvaccinated
Table 1 Bodyweight (BW) and average daily weight gain (ADWG) at different observation periods. Least square mean ± standard
error

















Number of animals 674 690 214 224 226 230 234 236
BW (kg) at
Vaccination 5.8 ± 0.05 5.8 ± 0.05 5.8 ± 0.09 5.7 ± 0.09 5.7 ± 0.09 5.7 ± 0.09 6.1 ± 0.09 6.1 ± 0.09
4 weeks post-
vaccination
14.6 ± 0.10 14.7 ± 0.10 14.4 ± 0.17 14.1 ± 0.17 15.1a ± 0.17 15.6b ± 0.17 14.2 ± 0.17 14.3 ± 0.16
10 weeks post-
vaccination
40.9a ± 0.23 41.5b ± 0.23 40.0 ± 0.41 39.4 ± 0.40 43.3a ± 0.42 44.9b ± 0.41 39.3 ± 0.40 40.4 ± 0.40
16–17 weeks post-
vaccination†





310 ± 3.5 314 ± 3.4 306 ± 6.1 295 ± 6.0 328a ± 6.1 347b ± 6.0 296 ± 5.9 300 ± 5.9
10 weeks post-
vaccination
486a ± 3.3 495b ± 3.2 474 ± 5.7 465 ± 5.6 519a ± 5.8 542b ± 5.7 465 ± 5.5 479 ± 5.5
16–17 weeks post-
vaccination†
602 ± 3.2 605 ± 3.1 597 ± 5.6 591 ± 5.5 638 ± 5.6 635 ± 5.5 573a ± 5.4 590b ± 5.4
BW homogeneity‡ (%) at
16–17 weeks post-
vaccination†
85a 86b 86 86 87 87 82a 85b
BW Bodyweight, ADWG Average Daily Weight Gain
† The end of the study was at 17 weeks post-vaccination in week groups 1 and 2, and at 16 weeks post-vaccination in week group 3
‡ BW homogeneity was calculated from coefficient of variation (1-CV). It was tested comparing variances of BW using an F test
a, b Within week group, different letter in the same row indicates statistically significant difference (p < 0.05). Differences between treatment groups were tested
using analysis of variance and subsequent t-tests
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pigs tested positive (see Figs. 2 and 3 at week 0). Not-
ably, none of the vaccinated animals tested positive by
PRRSV qPCR at the end of fattening while 3 % of the
unvaccinated animals were still viremic at the end of
fattening.
Percentages of pigs detected serologically positive by
ELISA were determined in vaccinated and unvaccinated
pigs. It was observed that 67 % (55–77 %; 95 % CI) of
vaccinated pigs and 75 % (63–85 %; 95 % CI) of unvac-
cinated pigs were seropositive at vaccination, and that
99 % (92–100 %; 95 % CI) of vaccinated pigs and 92 %
(83–98 %; 95 % CI) of unvaccinated pigs were already
seropositive at 4 weeks post-vaccination. For all time
points within this study, there was not statistical differ-
ence in the seroconversion rate between vaccinated and
control pigs.
Since the wild type PRRSV infection took place very
early during (WG 1) or after (WG 2 and WG 3) vaccin-
ation, it was not possible to determine the source of
viremia in vaccinated animals.
Fig. 2 Viremia in % positive pigs (qualitative) by qPCR at the different sampling times in 73 vaccinated pigs (24, 23 and 26 in week groups 1, 2
and 3, respectively). Percentage of positive pigs and confidence interval 95 %
Fig. 3 Viremia in % positive pigs (qualitative) by qPCR at the different sampling times in 69 unvaccinated pigs (22, 24 and 23 in weeks groups 1,
2 and 3, respectively). Percentage of positive pigs and confidence interval 95 %
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Table 2 summarizes the mortality, clinical signs and
concomitant treatments throughout the study. Proportion
of pigs showing any abnormal clinical sign at least once at
any of the examination time points was lower (p < 0.05) in
vaccinated pigs than in unvaccinated pigs, being the high-
est difference in WG 3 pigs. The most frequent signs were
respiratory and skin alterations, being in both instance the
proportion of affected pigs lower (p < 0.05) in vaccinated
pigs than in unvaccinated (p < 0.05). Prevalence of joint
disorders and diarrhea was generally low (1 % or lower).
Regarding concomitant treatments (Table 2), the pro-
portion of vaccinated pigs treated individually at least
once with a parenteral treatment was lower than in unvac-
cinated pigs (p < 0.05). The highest difference between
vaccinated and unvaccinated pigs was in WG 2. About
98 % of the individual treatments administered were with
injectable Enrofloxacin due to respiratory signs and in
some cases due to diarrhea. Although collective treat-
ments were restricted, a treatment with Doxycycline in
water was administered to all piglets for 6 days once. The
whole population was medicated including vaccinates and
controls but as pigs of different ages were treated this oc-
curred at a different time point in relation to the day of
vaccination. Medication was at 4, 3 and 2 weeks post-
vaccination in WG 1, WG 2 and WG 3, respectively. This
treatment was administered due to respiratory signs
(sneezing and coughing), but also rough haircoat and thin-
ness observed affecting all nursery rooms on the farm.
While numerically lower, there was no difference in
mortality rate between vaccinated and unvaccinated
pigs neither in the overall study nor within replicate
groups (Table 2). None of the dead pigs examined in
both treatment groups revealed PRRS related gross
necropsy findings. The incidence of the findings re-
corded did not provide indications of a treatment-
related pattern.
Discussion
This large field study was performed to investigate the
efficacy of a novel PRRS MLV vaccine in terms of zoo-
technical parameters (BW and ADGW), in piglets of
4 weeks of age that originated from a vaccinated sow
farm undergoing an active infection with a wild type
PRRSV.
Vaccinated pigs showed better growth parameters than
unvaccinated pigs at 10 weeks after vaccination. This
performance improvement was observed in the critical
period of virus circulation supporting the efficacy of the
vaccine. When analyzing the data by separate cohorts it
is clear that there were different responses to vaccin-
ation. Statistically significant differences for BW and
ADWG at the end of the study were observed only in
WG 3 pigs. Very few well controlled PRRS field trials
have been conducted in Europe. The differences in BW
and in ADWG observed among treatment groups in this
study were not as remarkable as in previous reports
[14–17]. Probably, this is due to the short time between
the vaccination and the occurrence of the natural infec-
tion, which did not allow for better performance in vac-
cinated animals. In particular, the improvement in BW
and ADWG could not be demonstrated in WG 1 prob-
ably because of a PRRSV wild type infection at the time
of vaccination. This was confirmed through qPCR test-
ing of pig sera at study day −1 before vaccination which
showed 33 % PRRSV RNA pigs. In addition most of
Table 2 Percentage of mortality, pigs with clinical signs and pigs received concomitant treatments throughout the study (95 % CI)

















Number of animals 674 690 214 224 226 230 234 236
Mortality (%) 6.1 4.9 5.1 3.6 5.8 4.8 7.3 6.4
(4.5–8.2) (3.6–6.8) (2.9–9.0) (1.8–6.9) (3.4–9.6) (2.7–8.4) (4.6–11.3) (3.9–10.2)
Any clinical sign (%)† 8.3a 4.2b 7.0 3.6 6.2 3.0 11.5a 5.9b
(6.5–10.6) (2.9–6.0) (4.3–11.2) (1.8–6.9) (3.7–10.1) (1.5–6.2) (8.1–16.3) (3.6–9.7)
Respiratory signs (%) 4.7a 2.3b 3.3 1.8 3.1 1.3 7.7 3.8‡
(3.4–6.6) (1.4–3.7) (1.6–6.6) (0.7–4.5) (1.5–6.3) (0.4–3.8) (4.9–11.8) (2.0–7.1)
Skin alterations (%) 2.4a 0.7b 2.3 0.9 1.3 0.4 3.4 0.8
(1.5–3.8) (0.3–1.7) (1.0–5.4) (0.3–3.2) (0.5–3.8) (0.8–2.4) (1.7–6.6) (0.2–3.0)
Concomitant
treatments (%)
23.0a 18.6b 15.5 15.6 21.2a 12.2b 32.5 27.5
(20.0–26.3) (15.8–21.6) (10.4–19.8) (11.5–21.0) (16.4–27.0) (8.6–17.0) (26.8–38.7) (22.2–33.6)
95 % CI: Wilson’s Confidence Interval 95 % for a single proportion
† Respiratory signs and/or skin alterations and/or joint disorders and/or diarrhoea. Prevalence of joint disorders and diarrhoea was 1 % or lower
a, b Within week group, different letter in the same row indicates statistically significant difference (p < 0.05). Differences between the treatment groups were
tested by Fisher’s exact test
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those previous studies were conducted in PRRS geno-
type 2 outbreaks under US conditions.
Proper vaccination against PRRSV or any MLV vac-
cines involves immunization of healthy pigs and proper
timing of the vaccination event in relationship to onset
of disease pressure on the farm. Under field conditions,
the onset of immunity could be adversely affected by the
presence of confounding factors, including the presence
of other pathogens and vaccination in the face of an on-
going active PRRSV infection [14].
The interpretation of these results has to be done con-
sidering these circumstances; however, it seems that the
vaccine protection even in the face of an existing infec-
tion was able to result in differences in BW and ADGW
at 10 weeks of age. As the end of the study was set as
the time when the first batch of pigs was sent to the
slaughterhouse, we do not know if these differences
carry over to batch closeout, where the entire economic
impact is assessed by the producers.
Respiratory clinical signs, skin alterations and con-
comitant treatments were all found to be significantly
reduced in vaccinated animals compared to unvaccin-
ated animals suggesting a beneficial effect of vaccination
on secondary infections and the general health status of
the animals. Mortality was not statistically different be-
tween vaccinated and control pigs. This and other clin-
ical parameters could be affected by the medication with
Doxycycline to the population.
None of the necropsies performed during the study
showed macroscopic signs of PRRSV infection, but de-
tailed diagnostics of each case were not performed.
While mortality was somewhat elevated at 4.9 and 6.1 %
(vaccinated vs. control, respectively) it was lower than in
other field studies that demonstrated statistical differ-
ences in reduction of mortality after vaccination [15].
We can assess that mortality was caused mainly by sec-
ondary infections in this trial (data not shown) as has
been the case of other studies [18]. A more detailed
diagnostic investigation of the deaths in this trial could
help explain the lack of statistical reduction in mortality.
At inclusion in the study at 4 weeks of age most ani-
mals were serologically positive. This might be due to
maternally derived antibodies from vaccinated dams or
already signals the ongoing field infection that started
during the suckling period. As vaccination is recom-
mended from 17 days of life onwards, maternally derived
antibodies should not have interfered with vaccination
and were not likely providing protection as many were
also positive for viral RNA. A limitation of this field
study, since the wild type PRRSV infection took place
very soon after vaccination or even before vaccination,
was that it was not possible to determine the source of
viremia in these animals. qPCR positive serum samples
could be due to vaccine virus, the field virus (being
viremic at vaccination time) or both as reported in other
studies [11]. Sequencing of all positive samples may have
provided further data to clarify this issue. Early PRRSV
infection in this trial highlights the importance of ensur-
ing breeding herd stability, defined by consistently wean-
ing PRRSV negative piglets, to maximize the benefit of
piglet vaccination [4, 17]. Other studies from North
America have demonstrated that the direct benefits of
PRRS vaccination in terms of efficacy depend on vaccin-
ation ahead of infection with field virus [14].
The PRRS field virus in this trial can be considered
heterologous to the vaccine virus (92.74 % homology in
ORF5). Murtaugh [19] indicates that a homology less or
equal than 97–98 % can be considered as a different
strain of the PRRSV, although the scientific community
has not agreed on a defined cut off. Even though signifi-
cant genetic differences were found between the strain
circulating before vaccination and the vaccine strain, the
vaccine provided partial clinical protection. However, to
better understand the dynamics of the infection and the
protection of the vaccine it would be advisable in future
studies to perform such type of analyses.
Conclusions
This study establishes that vaccination of piglets with
Ingelvac PRRSFLEX® EU at 4 weeks of age improves
weight gain and reduces the appearance of clinical sings
during the growing period, even when the piglets are in-
fected shortly after vaccination. Evidence of vaccine ben-
efits under field conditions was provided by improved
performance in the period during the onset and peak
viremia of wild-type PRRSV.
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